Madrid, 28 dic (EFE). – The Spanish Agency for Medicinal Products and Sanitary Products (AEMPS) has decided to maintain in the market the Briviactel medicines units that have a quality failure in their terms, but not in the product, which has provoked a “therapeutic lagoon”.
In a statement of this month, the AEMPS explains that at the moment there are no lots of this medicine available due to the incidence of quality and that the manufacturer is working to resolve this issue.
If a defect is found in some units of the drug Briviact 10 mg / ml oral solution, 300 ml, cuyos frascos have a diameter of the ligament that is more stratified in the establishment lesion, which differs the insertion of the adapter of the frasco into the ring orally.
However, Health is informed that it will inform the patient of this matter so that it can proceed to the replacement of the affected units.
Briviact contains the active principle of brivaracetam and belongs to a group of antiepileptic drugs.
The problem of the straight line of the phrase does not affect the quality and security of the oral solution in itself, assures Sanidad, which advises that “can not reduce a very small error of debiting debit to the use of the ring without the adapter” . EFE